A brief review of recent Charcot-Marie-Tooth research and priorities

F1000Research

Volumn 4, Issue , 2015, Pages

  Ekins, Sean ^a,b,c   Litterman, Nadia K ^c   Arnold, Renée J G ^d,e,f   Burgess, Robert W ^g   Freundlich, Joel S ^h   Gray, Steven J ⁱ   Higgins, Joseph J ^j   Langley, Brett ^k,l   Willis, Dianna E ^k   Notterpek, Lucia ^m   Pleasure, David ⁿ   Sereda, Michael W ^o,p   Moore, Allison ^a  

^a Hereditary Neuropathy Foundation   (United States)

^b Collaborations in Chemistry ^*  (United States)

^c Collaborative Drug Discovery ^*  (United States)

^d Arnold Consultancy and Technology LLC   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f Quorum Consulting Inc   (United States)

^g JACKSON LABORATORY   (United States)

^h RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^k Burke Cornell Medical Research Institute   (United States)

^l WEILL CORNELL MEDICAL COLLEGE   (United States)

^m UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^p UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BASIC RESEARCH; CLINICAL RESEARCH; CMT1A GENE; DIAGNOSTIC ACCURACY; GENE; GENE FREQUENCY; GENE MUTATION; GENE THERAPY; GENETIC ASSOCIATION; GENETIC SCREENING; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; OUTCOMES RESEARCH; QUALITY OF LIFE; REVIEW; STEM CELL TRANSPLANTATION;

EID: 84931281940     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.6160.1     Document Type: Review

References (104)

1. Swinney DC Xia S: The discovery of medicines for rare diseases. Future Med Chem. 2014;6(9):987-1002. 25068983 10.4155/fmc.14.65
2. Groft SC: Rare diseases research: expanding collaborative translational research opportunities. Chest. 2013;144(1):16-23. 23880676 10.1378/chest.13-0606 3707172
3. Wood J Sames L Moore A: Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery. Drug Discov Today. 2013;18(21-22):1043-1051. 23968993 10.1016/j.drudis.2013.08.006
4. Might M Wilsey M: The shifting model in clinical diagnostics: how next-generation sequencing and families are altering the way rare diseases are discovered, studied, and treated. Genet Med. 2014;16(10):736-7. 24651604 10.1038/gim.2014.23
5. Itoh T Pleasure D: The future of research in neuropathy. JAMA Neurol. 2014;72(1):5-7. 25364864 10.1001/jamaneurol.2014.2346
6. Miyamoto BE Kakkis ED: The potential investment impact of improved access to accelerated approval on the development of treatments for low prevalence rare diseases. Orphanet J Rare Dis. 2011;6:49. 21733145 10.1186/1750-1172-6-49 3149566
7. Beaulieu CL Samuels ME Ekins S: A generalizable pre-clinical research approach for orphan disease therapy. Orphanet J Rare Dis. 2012;7:39. 22704758 10.1186/1750-1172-7-39 3458970
8. Sames L Moore A Arnold R: Recommendations to enable drug development for inherited neuropathies: Charcot-Marie-Tooth and Giant Axonal Neuropathy. F1000Res. 2014;3:83. 24860645 10.12688/f1000research.3751.2 4023663
9. Vaidya M: Ice bucket challenge cash may help derisk ALS drug research. Nat Med. 2014;20(10):1080. 25295924 10.1038/nm1014-1080
10. Scott S Kranz JE Cole J: Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 2008;9(1):4-15. 18273714 10.1080/17482960701856300
11. Perrin S: Preclinical research: Make mouse studies work. Nature. 2014;507(7493):423-425. 24678540 10.1038/507423a
12. Prinz F Schlange T Asadullah K: Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov. 2011;10(9):712. 21892149 10.1038/nrd3439-c1
13. Baell JB Holloway GA: New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53(7):2719-2740. 20131845 10.1021/jm901137j
14. Baell J Walters MA: Chemistry: Chemical con artists foil drug discovery. Nature. 2014;513(7519):481-3. 25254460 10.1038/513481a
15. Che J King FJ Zhou B: Chemical and biological properties of frequent screening hits. J Chem Inf Model. 2012;52(4):913-26. 22435989 10.1021/ci300005y
16. Sink R Gobec S Pear S: False positives in the early stages of drug discovery. Curr Med Chem. 2010;17(34):4231-55. 20939815 10.2174/092986710793348545
17. Ekins S Olechno J Williams AJ: Dispensing processes impact apparent biological activity as determined by computational and statistical analyses. PLoS One. 2013;8(5):e62325. 23658723 10.1371/journal.pone.0062325 3641061
18. McDonald GR Hudson AL Dunn SM: Bioactive contaminants leach from disposable laboratory plasticware. Science. 2008;322(5903):917. 18988846 10.1126/science.1162395
19. Sassano MF Doak AK Roth BL: Colloidal aggregation causes inhibition of G protein-coupled receptors. J Med Chem. 2013;56(6):2406-14. 23437772 10.1021/jm301749y 3613083
20. Waybright TJ Britt JR McCloud TG: Overcoming problems of compound storage in DMSO: solvent and process alternatives. J Biomol Screen. 2009;14(6):708-15. 19531665 10.1177/1087057109335670
21. Narang D Kerr PM Baserman J: Triton X-100 inhibits L-type voltage-operated calcium channels. Can J Physiol Pharmacol. 2013;91(4):316-24. 23627843 10.1139/cjpp-2012-0257
22. Williams AJ Ekins S Tkachenko V: Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. Drug Discov Today. 2012;17(13-14):685-701. 22426180 10.1016/j.drudis.2012.02.013
23. Southan C Williams AJ Ekins S: Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates. Drug Discov Today. 2013;18(1-2):58-70. 23159359 10.1016/j.drudis.2012.11.005
24. Orchard S A-Lazikani B Bryant S: Minimum information about a bioactive entity (MIABE). Nat Rev Drug Discov. 2011;10(9):661-9. 21878981 10.1038/nrd3503
25. Shun TY Lazo JS Sharlow ER: Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review. J Biomol Screen. 2011;16(1):1-14. 21160066 10.1177/1087057110389039
26. Hert J Irwin JJ Laggner C: Quantifying biogenic bias in screening libraries. Nat Chem Biol. 2009;5(7):479-83. 19483698 10.1038/nchembio.180 2783405
27. Ekins S Waller CL Bradley MP: Four disruptive strategies for removing drug discovery bottlenecks. Drug Discov Today. 2013;18(5-6):265-71. 23098820 10.1016/j.drudis.2012.10.007
28. Frye S Crosby M Edwards T: US academic drug discovery. Nat Rev Drug Discov. 2011;10(6):409-10. 21629285 10.1038/nrd3462
29. Hay M Thomas DW Craighead JL: Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1): 40-51. 24406927 10.1038/nbt.2786
30. DiVincenzo C Elzinga CD Medeiros AC: The allelic spectrum of Charcot-Marie-Tooth disease in over 17,000 individuals with neuropathy. Mol Genet Genomic Med. 2014;2(6):522-529. 25614874 10.1002/mgg3.106 4303222
31. Miller LJ Saporta AS Sottile SL: Strategy for genetic testing in Charcot-Marie-disease. Acta Myol. 2011;30(2):109-16. 22106713 10.1523/JNEUROSCI.1356-10.2010 3235845
32. Rangaraju S Verrier JD Madorsky I: Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice. J Neurosci. 2010;30(34):11388-97. 20739560 10.1523/JNEUROSCI.1356-10.2010 3478092
33. Kaya F Belin S Bourgeois P: Ascorbic acid inhibits PMP22 expression by reducing cAMP levels. Neuromuscul Disord. 2007;17(3):248-53. 17303424 10.1016/j.nmd.2006.12.008
34. England JD Gronseth GS Franklin G: Practice Parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009;72(2):185-92. 19056666 10.1212/01.wnl.0000336370.51010.a1
35. Ostern R Fagerheim T Hjellnes H: Diagnostic laboratory testing for Charcot-Marie-Tooth disease (CMT): the spectrum of gene defects in Norwegian patients with CMT and its implications for future genetic test strategies. BMC Med Genet. 2013;14:94. 24053775 10.1186/1471-2350-14-94 3849068
36. Murphy SM Laura M Fawcett K: Charcot-Marie-Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J Neurol Neurosurg Psychiatry. 2012;83(7):706-10. 22577229 10.1136/jnnp-2012-302451 3736805
37. Saporta AS Sottile SL Miller LJ: Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol. 2011;69(1):22-33. 21280073 10.1002/ana.22166 3058597
38. Ylikallio E Johari M Konovalova S: Targeted next-generation sequencing reveals further genetic heterogeneity in axonal Charcot-Marie-Tooth neuropathy and a mutation in HSPB1. Eur J Hum Genet. 2014;22(4):522-7. 23963299 10.1038/ejhg.2013.190 3953916
39. Yao P Fox PL: Aminoacyl-tRNA synthetases in medicine and disease. EMBO Mol Med. 2013;5(3):332-43. 23427196 10.1002/emmm.201100626 3598075
40. Latour P Thauvin-Robinet C Baudelet-Méry C: A major determinant for binding and aminoacylation of tRNA(Ala) in cytoplasmic Alanyl-tRNA synthetase is mutated in dominant axonal Charcot-Marie-Tooth disease. Am J Hum Genet. 2010;86(1):77-82. 20045102 10.1016/j.ajhg.2009.12.005 2801750
41. Jordanova A Irobi J Thomas FP: Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat Genet. 2006;38(2):197-202. 16429158 10.1038/ng1727
42. Antonellis A Ellsworth RE Sambuughin N: Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet. 2003;72(5):1293-9. 12690580 10.1086/375039 1180282
43. McLaughlin HM Sakaguchi R Liu C: Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy. Am J Hum Genet. 2010;87(4):560-6. 20920668 10.1016/j.ajhg.2010.09.008 2948804
44. Gonzalez M McLaughlin H Houlden H: Exome sequencing identifies a significant variant in methionyl-tRNA synthetase (MARS) in a family with late-onset CMT2. J Neurol Neurosurg Psychiatry. 2013;84(11):1247-9. 23729695 10.1136/jnnp-2013-305049 3796032
45. Vester A Velez-Ruiz G McLaughlin HM: A loss-of-function variant in the human histidyl-tRNA synthetase (HARS) gene is neurotoxic in vivo. Hum Mutat. 2013;34(1):191-9. 22930593 10.1002/humu.22210 3535524
46. Griffin LB Sakaguchi R McGuigan D: Impaired function is a common feature of neuropathy-associated glycyl-tRNA synthetase mutations. Hum Mutat. 2014;35(11):1363-71. 25168514 10.1002/humu.22681 4213347
47. Motley WW Seburn KL Nawaz MH: Charcot-Marie-Tooth-linked mutant GARS is toxic to peripheral neurons independent of wild-type GARS levels. PLoS Genet. 2011;7(12):e1002399. 22144914 10.1371/journal.pgen.1002399 3228828
48. Antonellis A Lee-Lin SQ Wasterlain A: Functional analyses of glycyl-tRNA synthetase mutations suggest a key role for tRNA-charging enzymes in peripheral axons. J Neurosci. 2006;26(41):10397-406. 17035524 10.1523/JNEUROSCI.1671-06.2006
49. Motley WW Talbot K Fischbeck KH: GARS axonopathy: not every neuron's cup of tRNA. Trends Neurosci. 2010;33(2):59-66. 20152552 10.1016/j.tins.2009.11.001 2822721
50. Fledrich R Stassart RM Sereda MW: Experimental Treatment of hereditary and acquired Neuropathies, in Pathological potential of neuroglia. V. Parpura and A. Verkhratsky, Editors. Springer.2014;437-472. 10.1007/978-1-4939-0974-2_19
51. Naef R Suter U: Many facets of the peripheral myelin protein PMP22 in myelination and disease. Micros Res Tech. 1998;41(5):359-371. 9672419 10.1002/(SICI)1097-0029(19980601)41:5&<359::AID-JEMT3&>3.0.CO;2-L
52. Fledrich R Stassart RM Klink A: Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A. Nat Med. 2014;20(9):1055-61. 25150498 10.1038/nm.3664
53. Inglese J Dranchak P Moran JJ: Genome editing-enabled HTS assays expand drug target pathways for Charcot-Marie-tooth disease. ACS Chem Biol. 2014;9(11):2594-602. 25188731 10.1021/cb5005492 4245164
54. Jang SW Lopez-Anido C MacArthur R: Identification of drug modulators targeting gene-dosage disease CMT1A. ACS Chem Biol. 2012;7(7):1205-13. 22530759 10.1021/cb300048d 3401360
55. Nicks J Lee S Harris A: Rapamycin improves peripheral nerve myelination while it fails to benefit neuromuscular performance in neuropathic mice. Neurobiol Dis. 2014;70:224-36. 25014022 10.1016/j.nbd.2014.06.023
56. Lee S Amici S Tavori H: PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts. J Neurosci. 2014;34(48):16140-52. 25429154 10.1523/JNEUROSCI.1908-14.2014 4244477
57. Rivieccio MA Brochier C Willis DE: HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci U S A. 2009;106(46):19599-604. 19884510 10.1073/pnas.0907935106 2780768
58. d'Ydewalle C Krishnan J Chiheb DM: HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med. 2011;17(8):968-74. 21785432 10.1038/nm.2396
59. Zhu J Chen W Mi R: Ethoxyquin prevents chemotherapy-induced neurotoxicity via Hsp90 modulation. Ann Neurol. 2013;74(6):893-904. 23955554 10.1002/ana.24004
60. Chittoor-Vinod VG Lee S Judge SM: Inducible HSP70 Is Critical in Preventing the Aggregation and Enhancing the Processing of PMP22. ASN Neuro. 2015;7(1):1-17. 25694550 10.1177/1759091415569909
61. Fledrich R Stassart RM Sereda MW: Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease. Br Med Bull. 2012;102(1):89-113. 22551516 10.1093/bmb/lds010
62. Klein D Groh J Wettmarshausen J: Nonuniform molecular features of myelinating Schwann cells in models for CMT1: distinct disease patterns are associated with NCAM and c-Jun upregulation. Glia. 2014;62(5):736-50. 24526449 10.1002/glia.22638
63. Bogdanik LP Sleigh JN Tian C: Loss of the E3 ubiquitin ligase LRSAM1 sensitizes peripheral axons to degeneration in a mouse model of Charcot-Marie-Tooth disease. Dis Model Mech. 2013;6(3):780-92. 23519028 10.1242/dmm.010942 3634660
64. Seburn KL Morelli KH Jordanova A: Lack of neuropathy-related phenotypes in hint1 knockout mice. J Neuropathol Exp Neurol. 2014;73(7):693-701. 24918641 10.1097/NEN.0000000000000085 4098130
65. Chapman AL Bennett EJ Ramesh TM: Axonal Transport Defects in a Mitofusin 2 Loss of Function Model of Charcot-Marie-Tooth Disease in Zebrafish. PLoS One. 2013;8(6):e67276. 23840650 10.1371/journal.pone.0067276 3694133
66. Cherry S Jin EJ Ozel MN: Charcot-Marie-Tooth 2B mutations in rab7 cause dosage-dependent neurodegeneration due to partial loss of function. Elife. 2013;2:e01064. 24327558 10.7554/eLife.01064 3857549
67. Janssens K Goethals S Atkinson D: Human Rab7 mutation mimics features of Charcot-Marie-Tooth neuropathy type 2B in Drosophila. Neurobiol Dis. 2014;65:211-9. 24521780 10.1016/j.nbd.2014.01.021
68. Ermanoska B Motley WW Leitão-Gonçalves R: CMT-associated mutations in glycyl- and tyrosyl-tRNA synthetases exhibit similar pattern of toxicity and share common genetic modifiers in Drosophila. Neurobiol Dis. 2014;68:180-9. 24807208 10.1016/j.nbd.2014.04.020 4086162
69. Storkebaum E Leitão-Gonçalves R Godenschwege T: Dominant mutations in the tyrosyl-tRNA synthetase gene recapitulate in Drosophila features of human Charcot-Marie-Tooth neuropathy. Proc Natl Acad Sci U S A. 2009;106(28):11782-7. 19561293 10.1073/pnas.0905339106 2702257
70. Sahenk Z Galloway G Clark KR: AAV1.NT-3 gene therapy for Charcot-Marie-Tooth neuropathy. Mol Ther. 2014;22(3):511-21. 24162799 10.1038/mt.2013.250 3944324
71. Mussche S Devreese B Nagabhushan Kalburgi S: Restoration of cytoskeleton homeostasis after gigaxonin gene transfer for giant axonal neuropathy. Hum Gene Ther. 2013;24(2):209-19. 23316953 10.1089/hum.2012.107
72. Inoue H Nagata N Kurokawa H: iPS cells: a game changer for future medicine. EMBO J. 2014;33(5):409-17. 24500035 10.1002/embj.201387098 3989624
73. Yamanaka S: Induced pluripotent stem cells: past, present, and future. Cell Stem Cell. 2012;10(6):678-84. 22704507 10.1016/j.stem.2012.05.005
74. Surani MA: Cellular reprogramming in pursuit of immortality. Cell Stem Cell. 2012;11(6):748-50. 23217420 10.1016/j.stem.2012.11.014
75. Wu SM Hochedlinger K: Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol. 2011;13(5):497-505. 21540845 10.1038/ncb0511-497 3617981
76. Johnson-Kerner BL Ahmad FS Diaz AG: Let alIntermediate filament protein accumulation in motor neurons derived from giant axonal neuropathy iPSCs rescued by restoration of gigaxonin. Hum Mol Genet. 2014;24(5):1420-31. 25398950 10.1093/hmg/ddu556
77. Saporta MA Dang V Volfson D: Axonal Charcot-Marie-Tooth disease patient-derived motor neurons demonstrate disease-specific phenotypes including abnormal electrophysiological properties. Exp Neurol. 2015;263:190-9. 25448007 10.1016/j.expneurol.2014.10.005 4262589
78. Ma MS Boddeke E Copray S: Pluripotent Stem Cells for Schwann Cell Engineering. Stem Cell Rev. 2014. 25433863 10.1007/s12015-014-9577-1
79. Liu Q Spusta SC Mi R: Human neural crest stem cells derived from human ESCs and induced pluripotent stem cells: induction, maintenance, and differentiation into functional schwann cells. Stem Cells Transl Med. 2012;1(4):266-78. 23197806 10.5966/sctm.2011-0042 3659695
80. Menendez L Kulik MJ Page AT: Directed differentiation of human pluripotent cells to neural crest stem cells. Nat Protoc. 2013;8(1):203-12. 23288320 10.1038/nprot.2012.156
81. Ekins S Clark AM Swamidass SJ: Bigger data, collaborative tools and the future of predictive drug discovery. J Comput Aided Mol Des. 2014;28(10):997-1008. 24943138 10.1007/s10822-014-9762-y 4198464
82. Litterman NK Ekins S: Databases and collaboration require standards for human stem cell research. Drug Discov Today. 2015;20(2):247-254. 25449658 10.1016/j.drudis.2014.10.006
83. Anon: NIH Blueprint Neurotherapeutics Network. Neuroscience research. 2014. Reference Source
84. Hohn M Gregory K Chibale K: Novel web-based tools combining chemistry informatics, biology and social networks for drug discovery. Drug Discov Today. 2009;14(5-6):261-70. 19231313 10.1016/j.drudis.2008.11.015
85. Ekins S Williams AJ Krasowski MD In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today. 2011;16(7-8):298-310. 21376136 10.1016/j.drudis.2011.02.016
86. Litterman NK Lipinski CA Bunin BA: Computational prediction and validation of an expert's evaluation of chemical probes. J Chem Inf Model. 2014;54(10):2996-3004. 25244007 10.1021/ci500445u
87. Dortch RD Dethrage LM Gore JC: Proximal nerve magnetization transfer MRI relates to disability in Charcot-Marie-Tooth diseases. Neurology. 2014;83(17):1545-53. 25253751 10.1212/WNL.0000000000000919 4222857
88. Fridman V Bundy B Reilly MM: CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis. J Neurol Neurosurg Psychiatry. 2014. 25430934 10.1136/jnnp-2014-308826
89. Anon. Addex Announces Positive Data with ADX71441 in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease, Addex press release.2013. Reference Source
90. Chumakov I Milet A Cholet N: Polytherapy with a combination of three repurposed drugs (PXT-3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy. Orphanet J Rare Dis. 2014;9(1):201. 25491744 10.1186/s13023-014-0201-x 4279797
91. Attarian S Vallat JM Magy L: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT-3003) in patients with Charcot-Marie-Tooth disease type 1A. Orphanet J Rare Dis. 2014;9(1):199. 25519680 10.1186/s13023-014-0199-0 4311411
92. Tulchin-Francis KW Stevens W Jr Jeans KA: Intensity and duration of activity bouts decreases in healthy children between 7 and 13 years of age a new higher resolution method to analyze StepWatch Activity Monitor data. Physiol Meas. 2014;35(11):2239-54. 25340461 10.1088/0967-3334/35/11/2239
93. Schmidt AL Pennypacker ML Thrush AH: Validity of the StepWatch Step Activity Monitor: preliminary findings for use in persons with Parkinson disease and multiple sclerosis. J Geriatr Phys Ther. 2011;34(1):41-5. 21937891 10.1519/JPT.0b013e31820aa921
94. Mannil M Solari A Leha A: Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscul Disord. 2014;24(11):1003-17. 25085517 10.1016/j.nmd.2014.06.431
95. Padua L Pazzaglia C Schenone A: Rehabilitation for Charcot-Marie-Tooth: a survey study of patients and familiar/caregiver perspective and perception of efficacy and needs. Eur J Phys Rehabil Med. 2014;50(1):25-30. 24285024
96. Beitz J Gnecco C Justice R: Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective. J Natl Cancer Inst Monogr. 1996;20:7-9. 8750460
97. Shah SN Sesti AM Copley-Merriman K: Quality of life terminology included in package inserts for US approved medications. Qual Life Res. 2003;12(8):1107-17. 14651428 10.1023/A:1026187402267
98. Colomban C Micallef J Lefebvre MN: Clinical spectrum and gender differences in a large cohort of Charcot-Marie-Tooth type 1A patients. J Neurol Sci. 2014;336(1-2):155-60. 24246498 10.1016/j.jns.2013.10.029
99. Ramchandren S Jaiswal M Feldman E: Effect of pain in pediatric inherited neuropathies. Neurology. 2014;82(9):793-7. 24477108 10.1212/WNL.0000000000000173 3945655
100. Ekins S Waller CL Bradley MP: Four disruptive strategies for removing drug discovery bottlenecks. Drug Disc Today. 2013;18(5-6):265-271. 23098820 10.1016/j.drudis.2012.10.007
101. Murphy SM Herrmann DN McDermott MP: Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2011;16(3):191-8. 22003934 10.1111/j.1529-8027.2011.00350.x 3754828
102. Mattson MP Allisonc DB Fontana L: Meal frequency and timing in health and disease. Proc Natl Acad Sci U S A. 2014;111(47):16647-53. 25404320 10.1073/pnas.1413965111 4250148
103. Kaya F Belin S Diamantidis G: Ascorbic acid is a regulator of the intracellular cAMP concentration: old molecule, new functions? FEBS Lett. 2008;582(25-26):3614-8. 18835269 10.1016/j.febslet.2008.09.040
104. Anon. Dose Dependently Reduced PMP22 Expression Comparable to Baclofen in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease. Addex Therapeutics. 2013. Reference Source